Tempus confirmed the acquisition of pharmacogenetics assets from the recently defunct OneOme, including the RightMed PGx business and its customer partnerships. OneOme’s abrupt shutdown left clients scrambling; Tempus said the deal strengthens its PGx offerings and brings OneOme’s health‑system relationships and report formats into Tempus’ commercial footprint. The move fits Tempus’ broader M&A strategy to expand genomics and clinical testing capabilities and underscores ongoing consolidation in the pharmacogenetics market as labs and test providers realign.